THTakahiro Horimatsu

Takahiro Horimatsu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Takahiro Horimatsu has a total of 373 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer

    by Masashi Tamaoki, Akira Yokoyama, Chikatoshi Katada, Kenshiro Hirohashi, Yosuke Mitani, Yusuke Amanuma, Takahiro Horimatsu, Hirokazu Higuchi, Natsuko Yamahigashi, Motoo Nomura, et al.

    Background: Talaporfin sodium photodynamic therapy (Talaporfin-PDT) shows a high local complete response (L-CR) rate for local failure after chemoradiotherapy in esophageal cancer; however, some patients do not achieve L-CR. We investigated the treatment resistance factors associated with Talaporfin-PDT for local control. Methods: This study included 55 consecutive patients with ycT1-2 esophageal cancer who received Talaporfin-PDT. We investigated the L-CR rate, cumulative survival rate according to local effect, and treatment resistance factors associated with Talaporfin-PDT for local control using a multivariate logistic regression model. Results: The L-CR rate was 65.5% (95% confidence interval [CI]: 52.3–76.6). During the median follow-up of 17.8 months (range, 1.7–69.3), the 1-year overall survival (OS), progression-free survival (PFS), and disease-specific survival (DSS) rates were significantly higher in patients who achieved L-CR than in those who did not: 97.0% vs. 75.6% ( P = 0.008), 64.6% vs. 0% ( P < 0.001), and 97.0% vs. 85.7% ( P = 0.005), respectively. In the multivariate logistic regression model, esophageal stenosis before Talaporfin-PDT was an independent predictor of local failure after Talaporfin-PDT (odds ratio: 5.626, 95% CI: 1.051–30.124, P = 0.044). The 1-year OS and DSS rates were significantly lower in patients with stenosis before Talaporfin-PDT than in those without: 75.0% vs. 92.4% ( P = 0.015) and 85.7% vs. 94.6% ( P = 0.015), respectively. Conclusions: Esophageal stenosis before Talaporfin-PDT was associated with resistance to local control and poor survival. The indications for the use of Talaporfin-PDT in patients with stenosis should be considered carefully.


  • Open Access

    Long-term outcome of PDT for local failure after CRT or RT for oesophageal cancer

    by Takahiro Horimatsu, Tomonori Yano, Yoshinobu Yamamoto, Hiromi Kataoka, Yohei Yabuuchi, Ryu Ishihara, Hiroi Kasai, Ryuji Uozumi, Harue Tada, Manabu Muto

    Background: The long-term local control and effect of photodynamic therapy (PDT) using talaporfin sodium and a diode laser (talaporfin PDT) on overall survival (OS) for local failure after chemoradiotherapy (CRT) for esophageal cancer are unknown. Here, we present a 5-year survival analysis for talaporfin PDT. Methods: This was a prospective follow-up analysis of an open-label, multicenter, phase 2 study of local failure after CRT or radiotherapy in patients who received talaporfin PDT. The primary endpoint was the overall OS. The secondary endpoints were progression-free survival (PFS), local progression-free survival (L-PFS) with local progression or recurrence and death as events, and local time to progression (L-TTP) with only local progression or recurrence as events. Results: Between November 2012 and December 2013, 26 patients with oesophageal squamous cell carcinoma underwent talaporfin PDT. The baseline T stages were cT1 in 14 patients, cT2 in 6 patients, and cT3 in 6 patients. Pre-PDT T stages were cT1b for 19 and cT2 for 7 patients, and no lymph nodes or distant metastases were detected. At a median 6.8-year follow-up, the median OS and 5-year OS rates were 4.2 years (95% confidence interval [CI]: 1.6–7.3) and 40.6% (95% CI: 21.7–58.7), respectively. The median PFS and L-PFS were 1.1 and 2.1 years, respectively. The 5-year local progression-free rate was 84.9%. No treatment-related deaths occurred. Conclusion: Talaporfin PDT for patients with oesophageal cancer with local failure after CRT can achieve long-term local complete response and long-term survival as a minimally invasive salvage treatment. Trial registration number: UMIN000009184.


  • A Randomized Controlled Trial of Betamethasone on Fatigue in Patients With Advanced Cancer

    by Kikuko Miyazaki, Masayuki Ikenaga, Tosiya Sato, Kenji Ueshima, Shuichi Nawata, Takahiro Horimatsu, Eisaku Komori, Toshihiko Kirishima, Kunihiro Kawabata, Takashi Kawamura, et al.


  • Open Access

    Supplementary Data from Efficacy of Low-Dose Aspirin in Colorectal Cancer Risk Prevention is Dependent on ADH1B and ALDH2 Genotype in Japanese Familial Adenomatous Polyposis Patients

    by Kanae Mure, Hideki Ishikawa, Michihiro Mutoh, Mano Horinaka, Takahiro Otani, Sadao Suzuki, Keiji Wakabayashi, Toshiyuki Sakai, Yasushi Sato, Hisashi Doyama, et al.

  • Interinstitutional differences in diagnosis of the morphology of colorectal polyps in Japan: a nationwide database analysis

    by Takahiro Utsumi, Takahiro Horimatsu, Yoshitaka Nishikawa, Hiroshi Seno

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    Short-term safety of adjuvant chemoradiotherapy after local resection for patients with high-risk submucosal invasive rectal cancer: a single-arm, multicenter phase II trial

    by Masaaki Noguchi, Kohei Shitara, Akihito Kawazoe, Daisuke Yamamoto, Yasumasa Takii, Yutaka Saito, Toshihiko Sato, Takahiro Horimatsu, Hideki Ishikawa, Yoshinori Ito, et al.

    Surgery is recommended for patients with high-risk submucosal invasive rectal cancer (SM-RC) after local resection but affects the quality of life due to stoma placement or impaired anal function; therefore, alternative treatment approaches are needed to prevent local metastasis. The purpose of this study was to assess the short-term safety of adjuvant chemoradiotherapy with capecitabine in patients with high-risk submucosal invasive rectal cancer after local resection. This single-arm, multicenter, phase II trial included patients undergoing local resection for high-risk submucosal invasive rectal cancer within 12 weeks prior to enrollment. High-risk submucosal invasive rectal cancer was defined as the presence of at least one of the following factors: poor differentiation of adenocarcinoma, submucosal invasion depth > 1 mm, presence of lymphovascular invasion and grade-2 or -3 tumour budding. Protocol treatment comprised 45.0 Gy radiotherapy with conventional fractionation and 1650 mg/m2 capecitabine given twice daily until radiotherapy completion. The primary endpoint was treatment completion rate with an expected rate of 95% and a threshold of 80%. Twenty-nine patients from six institutions were enrolled between May 2015 and February 2018. One patient was ineligible. Twenty-three patients completed treatment, with a completion rate of 82% (80% confidence interval, 69–91%); the remaining five patients completed treatment with protocol deviation. The median relative dose intensity of capecitabine was 100% (range, 58–100%). Common adverse events included radiation dermatitis (54%), anal pain (39%) and anal mucositis (29%). No grade-3 or higher adverse events were reported. Adjuvant chemoradiotherapy using capecitabine demonstrated acceptable short-term safety profiles in patients with high-risk submucosal invasive rectal cancer after local resection.


  • Measurement bias of colorectal polyp size: Analysis of the Japan Endoscopy Database

    by Takahiro Utsumi, Takahiro Horimatsu, Hiroshi Seno


  • Open Access

    Clinical Practice of Postoperative Adjuvant Chemotherapy in Patients with Colorectal Liver Metastases: Impact of the Completion for Six Months

    by Hiroto Nishino, Etsuro Hatano, Masayuki Okuno, Rei Toda, Satoru Seo, Kojiro Taura, Takahiro Horimatsu, Masashi Kanai, Suguru Hasegawa, Shigemi Matsumoto, et al.

  • PS02.038: SAFETY AND EFFICACY OF REPETITIVE PHOTODYNAMIC THERAPY FOR RESIDUAL ESOPHAGEAL CANCER LESIONS AFTER INITIAL PHOTODYNAMIC THERAPY

    by Masashi Tamaoki, Yusuke Amanuma, Takahiro Horimatsu, Shinya Ohashi, Manabu Muto

    Background Photodynamic therapy (PDT) is an effective salvage treatment for local failure after chemoradiotherapy in patients with esophageal cancers. However, the treatment strategy for local failure after initial PDT has not been established, and the safety and efficacy of repetitive PDT for such lesions are also unknown. Methods We retrospectively investigated 33 esophageal cancer patients who received initial salvage PDT at Kyoto University Hospital between May 2012 and November 2017. Additionally, we examined the treatment outcomes of those patients who received repetitive PDT. Results Twenty-one patients (64%) achieved local complete response (CR) by initial PDT, and local recurrence did not occur in those patients. Eleven patients (33%) had residual lesions after initial PDT. Among these, 7 patients were treated with repetitive PDT, 2 patients selected best supportive care, 1 patient was treated with surgery, and 1 patient was treated with chemotherapy. Five of the 7 patients who received repetitive PDT were treated with talaporfin sodium, and 2 patients were treated with porfimer sodium. The median age of the patients who received repetitive PDT was 70 years old, and all patients were men. Regarding histology, 6 patients were squamous cell carcinoma and 1 patient was adenocarcinoma. The median period from initial PDT to repetitive PDT was 3 months (range 1–4). Lesion depth before initial PDT was T1 in 3 patients and T2 in 4 patients. Lesion depth before repetitive PDT was T1 in 5 patients, and T2 in 2 patients. Local CR rate in 7 patients treated with repetitive PDT was 42.9% (3/7). Additionally, local CR rate in T1 cases was 60% and 0% in T2 cases. Adverse events of grade 3 or higher were not observed in any patient. Conclusion Repetitive salvage PDT was considered to be an effective and safe treatment option in residual T1 lesions after initial PDT for local failure of esophageal cancer treated with chemoradiotherapy. Disclosure All authors have declared no conflicts of interest.

  • PS02.034: EFFICACY AND SAFETY OF SALVAGE PHOTODYNAMIC THERAPY USING TALAPORFIN SODIUM FOR LOCAL FAILURE AFTER CHEMORADIOTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER

    by Yusuke Amanuma, Shinya Ohashi, Masashi Tamaoki, Takahiro Horimatsu, Manabu Muto

    Background We previously conducted an investigator-initiated trial of photodynamic therapy (PDT) using talaporfin sodium (talaporfin-PDT) and laser irradiation (PD-laser) against local failure after chemoradiotherapy (CRT) in patients with esophageal cancer (EC) and reported a high local complete response rate (L-CR) (88.5%) (Yano et al., Oncotarget 2017). Thereafter, talaporfin-PDT has been applied clinically as a salvage treatment for local failure after CRT in Japan since October 2015. The current study retrospectively reviewed the efficacy and safety of talaporfin-PDT in patients who underwent this treatment in our clinical practice. Methods This study was a single-center retrospective observational study. Patients who received salvage talaporfin-PDT for local failure of EC limited to T1–2 after definitive CRT or radiotherapy from May 2011 to July 2017 in our hospital were included. PDT was applied with an intravenous administration of talaporfin sodium (40 mg/kg) followed 4 h later by diode laser irradiation at 100 J/cm2. The primary and secondary endpoints were the rate of L-CR and the safety of PDT, respectively. The criteria for L-CR were as follows: 1) no residual tumor, 2) disappearance of post-PDT ulcer and scar formation, and 3) disappearance of cancer cells as assessed histologically. Results Thirty-one patients were analyzed in this study (26 men, 5 women, median age: 68 years). Histological types were squamous cell carcinoma and adenocarcinoma (30 and 1 patients, respectively). The failure patterns of lesions after CRT were recurrence after achieving a CR and residual lesion just after CRT (25 and 6 patients, respectively). The recurrent T stages were T1a, T1b, and T2 (1, 18, and 12 patients, respectively). The median total laser exposure dose was 500 J (range: 200–900). The L-CR rates were 84.2% (16/19), 41.7% (5/12), and 61.3% (19/31) in patients with T1, T2, and all stages, respectively. No severe adverse events greater than grade 3 related to PDT were observed. Although four patients had grade 2 esophageal stenosis after PDT, the stenosis was controlled by endoscopic balloon dilation. Conclusion Salvage talaporfin-PDT is a safe and curative treatment for local failure, especially stage T1, after CRT in patients with EC. Disclosure All authors have declared no conflicts of interest.